Two new cancer-causing gene mutations identified
Washington: Researchers, including one of Indian-origin, have identified two new cancer-causing gene mutations that may be susceptible to existing cancer-fighting drugs.
The discovery could lead to more targeted and effective treatments for certain lung and prostate cancers, researchers said.
Researchers said that cancers with the newly discovered mutations in the MCM8 and MCM9 genes likely will respond extremely favourably to the same chemotherapy drugs that have already proven effective against breast cancers with the well-known BRCA1 and BRCA2 gene mutations.
“One of the biggest problems in cancer is that we hit everything with the same hammer, and consequently some cancers are responsive and others are not,” said lead researcher Anindya Dutta of University of Virginia Cancer Centre in US.
“Imagine if you could find the perfect hammer for the nail – the famous personalised therapy,” Dutta said.
“If a patient has BRCA1 and BRCA2 mutations, then the perfect hammer is cisplatin and olaparib.
“Similarly, (for other cancers,) if you could break them up into those with mutations in MCM8 and MCM9, and then hit them hard with olaparib and cisplatin, we predict that there will be much better responsiveness,” Dutta said.
The research shows that the MCM8 and MCM9 genes produce proteins that play a critical role in homologous recombination, a method cells use to repair double-strand breaks in our DNA.
Such breaks are thought to occur commonly – perhaps thousands of times in each cell’s life – but the vital repair proteins appear to be missing in cancers with MCM8 and MCM9 mutations.
That defect could be the cancer cells’ downfall, theoretically making them “superbly sensitive” to cisplatin and other drugs already developed to battle BRCA1 and BRCA2 mutations, said Dutta.
As of now, there is no commercially available diagnostic test for the MCM8 and MCM9 mutations, though they could be revealed via whole genome sequencing.
Dutta said that he would also like to see a clinical trial to determine the effectiveness of cisplatin and olaparib in battling cancers with the MCM8 and MCM9 mutations.
Dutta’s research also notes the correlation of genetic inactivation of the MCM8 gene and the early onset of menopause, also known as premature ovarian failure.
The study was published in the journal Nature Communications.